Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems-Trading Strong Earnings Growth and Momentum -- Ignore unavailable to you. Want to Upgrade?

To: DanWebzster who wrote (3892)	2/6/2001 1:36:34 PM
From: Lane Hall-Witt	Respond to of 6445

Thanks, Dan, for the input on CEGE. I was aware that GVAX is perceived as a potential dud, commercially, but thought things looked a bit better as you go back in the pipeline. The thing that's always astonished me about CEGE is that it typically trades for only about 5-15 percent more the value of its cash, short-term investments, and ABGX holdings. At the moment, the portfolio of hundreds of patents and the existing pipeline have a market value of only $100 million or so. It just seems odd for a biotech company to get so little leverage out of its intellectual property, to say nothing of its own pipeline. The market's essentially telling CEGE that it should liquidate itself. (Maybe it should--.)